Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study

Sacituzumab-govitecan (Sgov) is a new antibody-drug conjugate recently approved for metastatic triple negative breast cancer (mTNBC), so there are still few data published in the real-world setting.